Early stage biotech Rubius Therapetics (RUBY) plans to transform red blood cells into therapies that can treat rare diseases caused by enzyme deficiencies and overcome resistance to existing cancer immunotherapies. Backed by blue chip VC Flagship Pioneering,...read more
Ten companies raised a combined $1.6 billion in the most active week of the 2017 IPO market. Texas community bank CBTX took the top spot with a 10% pop, which is still below the long term historical average of 13%. The week featured three...read more
Erytech Pharma, a French biotech developing enzyme-based therapies for rare cancers, raised $109 million by offering 4.7 million ADSs at $23.26. Listed on the Euronext Paris, it had provided a range of $23 to $24. The company also raised $16 million in a...read more
Erytech Pharma, a French biotech developing enzyme-based therapies for rare cancers, announced terms for its US IPO on Monday. The company's shares are currently listed on the Euronext Paris under they symbol ERYP. The Lyon, France-based company plans to...read more
Red Blood Cell Therapies: Worth $2 Billion or $200 Million?
Early stage biotech Rubius Therapetics (RUBY) plans to transform red blood cells into therapies that can treat rare diseases caused by enzyme deficiencies and overcome resistance to existing cancer immunotherapies. Backed by blue chip VC Flagship Pioneering,...read more
US IPO Weekly Recap: 10 companies go public in the busiest week of 2017
Ten companies raised a combined $1.6 billion in the most active week of the 2017 IPO market. Texas community bank CBTX took the top spot with a 10% pop, which is still below the long term historical average of 13%. The week featured three...read more
French cancer biotech Erytech Pharma prices US IPO at $23.26
Erytech Pharma, a French biotech developing enzyme-based therapies for rare cancers, raised $109 million by offering 4.7 million ADSs at $23.26. Listed on the Euronext Paris, it had provided a range of $23 to $24. The company also raised $16 million in a...read more
Cancer biotech Erytech Pharma sets terms for $100 million US IPO
Erytech Pharma, a French biotech developing enzyme-based therapies for rare cancers, announced terms for its US IPO on Monday. The company's shares are currently listed on the Euronext Paris under they symbol ERYP. The Lyon, France-based company plans to...read more